Search Results - "Dave Sharp, Zelton"
-
1
Acarbose improved survival for Apc+/Min mice
Published in Aging cell (01-02-2020)“…Acarbose blocks the digestion of complex carbohydrates, and the NIA Intervention Testing Program (ITP) found that it improved survival when fed to mice. Yet,…”
Get full text
Journal Article -
2
Rapamycin, the only drug that has been consistently demonstrated to increase mammalian longevity. An update
Published in Experimental gerontology (01-06-2023)Get full text
Journal Article -
3
Rapamycin‐mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction
Published in Aging cell (01-06-2014)“…Summary Rapamycin, an inhibitor of mTOR kinase, increased median lifespan of genetically heterogeneous mice by 23% (males) to 26% (females) when tested at a…”
Get full text
Journal Article -
4
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Published in Nature (London) (16-07-2009)“…Inhibition of the TOR signalling pathway by genetic or pharmacological intervention extends lifespan in invertebrates, including yeast, nematodes and…”
Get full text
Journal Article -
5
Activation of estrogen receptor-alpha by E2 or EGF induces temporally distinct patterns of large-scale chromatin modification and mRNA transcription
Published in PloS one (28-05-2008)“…Estrogen receptor-alpha (ER) transcription function is regulated in a ligand-dependent (e.g., estradiol, E2) or ligand-independent (e.g., growth factors)…”
Get full text
Journal Article -
6
eRapa Restores a Normal Life Span in a FAP Mouse Model
Published in Cancer prevention research (Philadelphia, Pa.) (01-01-2014)“…Mutation of a single copy of the adenomatous polyposis coli (APC) gene results in familial adenomatous polyposis (FAP), which confers an extremely high risk…”
Get full text
Journal Article -
7
Evidence for Down-Regulation of Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin (PI3K/Akt/mTOR)-Dependent Translation Regulatory Signaling Pathways in Ames Dwarf Mice
Published in The journals of gerontology. Series A, Biological sciences and medical sciences (01-03-2005)“…How growth hormone (GH) stimulates protein synthesis is unknown. Phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathways…”
Get full text
Journal Article -
8
mTOR inhibitors for treatment of low-risk prostate cancer
Published in Medical hypotheses (01-08-2018)“…Prostate cancer incidence increases with age; along with many other cancers, it could be considered a disease of aging. Prostate cancer screening has led to a…”
Get full text
Journal Article -
9
Aging and cancer: can mTOR inhibitors kill two birds with one drug?
Published in Targeted oncology (01-03-2011)“…The main risk factor for a number of diseases, including cancer, is aging. By delaying the effects of aging, many years of research indicate that diseases…”
Get full text
Journal Article -
10
Adaptations to chronic rapamycin in mice
Published in Pathobiology of aging & age related diseases (2016)“…Rapamycin inhibits mechanistic (or mammalian) target of rapamycin (mTOR) that promotes protein production in cells by facilitating ribosome biogenesis (RiBi)…”
Get full text
Journal Article -
11
Rapamycin, the only drug that consistently demonstrated to increase mammalian longevity. An update
Published in Experimental gerontology (07-04-2023)Get full text
Journal Article -
12
Abstract 671: mTORC1 suppression in Paneth cells prevents tumors in a mouse model of intestinal cancer
Published in Cancer research (Chicago, Ill.) (15-08-2020)“…Abstract The mechanistic (or mammalian) target of rapamycin, mTOR, is a highly conserved PI3K-related kinase that regulates cell growth, proliferation,…”
Get full text
Journal Article -
13
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice
Published in The journals of gerontology. Series A, Biological sciences and medical sciences (01-02-2011)“…Rapamycin was administered in food to genetically heterogeneous mice from the age of 9 months and produced significant increases in life span, including…”
Get full text
Journal Article -
14
mTORC1 and p53: Clash of the gods?
Published in Cell cycle (Georgetown, Tex.) (01-01-2013)“…A balance must be struck between cell growth and stress responses to ensure that cells proliferate without accumulating damaged DNA. This balance means that…”
Get full text
Journal Article -
15
Rapamycin Extends Life Span in Apc Colon Cancer FAP Model
Published in Clinical colorectal cancer (01-03-2021)Get full text
Journal Article -
16
Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune‐deficient mice
Published in Aging cell (01-12-2015)“…Summary The mammalian (mechanistic) target of rapamycin (mTOR) regulates critical immune processes that remain incompletely defined. Interest in mTOR inhibitor…”
Get full text
Journal Article -
17
-
18
Aging and TOR: interwoven in the fabric of life
Published in Cellular and molecular life sciences : CMLS (01-02-2011)“…Longstanding results with calorie and growth factor restriction plus recent results with the first interventional drug suggest that retarding the pace of aging…”
Get full text
Journal Article -
19
Rapamycin Extends Life Span in ApcMin/+ Colon Cancer FAP Model
Published in Clinical colorectal cancer (01-03-2021)“…We previously showed that lifelong rapamycin treatment of short-lived ApcMin/+ mice, a model for familial adenomatous polyposis, resulted in a normal lifespan…”
Get full text
Journal Article -
20
Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors
Published in Aging (Albany, NY.) (01-02-2013)“…Chronic treatment of mice with an enterically released formulation of rapamycin (eRapa) extends median and maximum life span, partly by attenuating cancer. The…”
Get full text
Journal Article